A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01928394
Recruitment Status : Active, not recruiting
First Posted : August 23, 2013
Last Update Posted : December 7, 2017
Information provided by (Responsible Party):
Bristol-Myers Squibb